Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Nov;100(11):1547-1550.
doi: 10.1136/bjophthalmol-2015-306930. Epub 2016 Jan 28.

Long-term outcome after topical ciclosporin in severe dry eye disease with a 10-year follow-up

Morgane Straub  1 , Alain M Bron  2   3 , Aurore Muselier-Mathieu  2 , Catherine Creuzot-Garcher  2   3
Affiliations
Clinical Trial

Long-term outcome after topical ciclosporin in severe dry eye disease with a 10-year follow-up

Morgane Straub et al. Br J Ophthalmol. 2016 Nov.

Abstract

Aim: To report a 10-year follow-up of patients suffering from severe dry eye syndrome (DES) initially treated with topical ciclosporin A (tCSA) for 6 months.

Methods: The charts of 26 patients with severe DES related to keratoconjunctivitis sicca (KCS) and followed for a minimum 10-year follow-up were retrospectively reviewed. All of them were treated initially with tCSA for 6 months. The Schirmer I test, fluorescein and lissamine green staining scores and tear film break-up time (TBUT) were recorded to assess clinical symptoms before, during and after treatment. The subjective signs were evaluated with the ocular surface disease index (OSDI) questionnaire. Prolongation and reintroduction of tCSA after the initial treatment and combined treatments were also noted.

Results: Overall the median (IQR) duration of tCSA treatment was 23 (7-51) months after a prolonged induction treatment lasting 20 (8-41) months during the 10-year follow-up. For symptoms, a statistically significant difference in the OSDI between baseline and the end of the 10-year follow-up was not found (p=0.67). We noted a statistically significant improvement in all clinical signs after the initial treatment period, still present at the end of follow-up. Only 6.5% of the patients needed reintroduction of tCSA after their prolonged induction treatment.

Conclusions: The improvement observed after an initial tCSA treatment was sustained after a long-term follow-up with few cases requiring additional tCSA treatment. A prolonged induction treatment to decrease initial inflammatory local signs is a promising option in KCS.

Keywords: Inflammation; Ocular surface; Tears.

PubMed Disclaimer

Conflict of interest statement

Competing interests: AMB: consultant for Allergan, Bausch Lomb, Théa, research grant Horus; CC-G: consultant for Allergan, Bayer, Bausch Lomb, Novartis, Théa, research grant Horus.

Figures

Figure 1
Figure 1
Flow chart of the ‘Long-term outcome after topical cyclosporine in severe dry eye disease with a 10-year follow-up’ study.
See this image and copyright information in PMC

References

    1. Lemp MA. Report of the national eye institute/industry workshop on clinical trials in dry eyes. CLAO J 1995;21:221–32. - PubMed
    1. Pflugfelder SC. Prevalence, burden, and pharmacoeconomics of dry eye disease. Am J Manag Care 2008;14:S102–6. - PubMed
    1. Smith VA, Rishmawi H, Hussein H, et al. . Tear film MMP accumulation and corneal disease. Br J Ophthalmol 2001;85:147–53. 10.1136/bjo.85.2.147 - DOI - PMC - PubMed
    1. Yüksel B, Bozdağ B, Acar M, et al. . Evaluation of the effect of topical cyclosporine A with impression cytology in dry eye patients. Eur J Ophthalmol 2010;20:675–9. - PubMed
    1. Sall K, Stevenson OD, Mundorf TK, et al. . Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000;107:631–9. - PubMed

Publication types

MeSH terms